title: Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP.
abstract: To identify clinical and electrophysiologic features related to IV immunoglobulin (IVIg) responsiveness in chronic inflammatory demyelinating polyneuropathy (CIDP), the authors conducted a multicenter study on 312 patients with CIDP (199 responders and 113 nonresponders). Muscle atrophy and decreased compound muscle action potential were pronounced in nonresponders of IVIg. Male gender, longer disease duration, and slow progression of symptoms were also associated with IVIg unresponsiveness. Features suggesting axonal dysfunction in peripheral nerves indicated IVIg unresponsiveness in CIDP.
authors.affiliation: Department of Neurology, Nagoya University Graduate School of Medicine, Tsurumai, Nagoya, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Iijima
authors.forename: M
authors.initials: M
authors.lastname: Yamamoto
authors.forename: M
authors.initials: M
authors.lastname: Hirayama
authors.forename: F
authors.initials: F
authors.lastname: Tanaka
authors.forename: M
authors.initials: M
authors.lastname: Katsuno
authors.forename: K
authors.initials: K
authors.lastname: Mori
authors.forename: H
authors.initials: H
authors.lastname: Koike
authors.forename: N
authors.initials: N
authors.lastname: Hattori
authors.forename: K
authors.initials: K
authors.lastname: Arimura
authors.forename: M
authors.initials: M
authors.lastname: Nakagawa
authors.forename: H
authors.initials: H
authors.lastname: Yoshikawa
authors.forename: K
authors.initials: K
authors.lastname: Hayasaka
authors.forename: O
authors.initials: O
authors.lastname: Onodera
authors.forename: M
authors.initials: M
authors.lastname: Baba
authors.forename: H
authors.initials: H
authors.lastname: Yasuda
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: M
authors.initials: M
authors.lastname: Nakazato
authors.forename: K
authors.initials: K
authors.lastname: Nakashima
authors.forename: J
authors.initials: J
authors.lastname: Kira
authors.forename: R
authors.initials: R
authors.lastname: Kaji
authors.forename: N
authors.initials: N
authors.lastname: Oka
authors.forename: G
authors.initials: G
authors.lastname: Sobue
mesh_terms: D000328:Adult; D017668:Age of Onset; D000368:Aged; D001369:Axons / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D018450:Disease Progression; D004351:Drug Resistance / Q000276:immunology; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009046:Motor Neurons / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D009133:Muscular Atrophy / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D009431:Neural Conduction / Q000187:drug effects / Q000276:immunology; D009475:Neurons, Afferent / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D010525:Peripheral Nerves / Q000187:drug effects* / Q000276:immunology / Q000503:physiopathology*; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D012737:Sex Factors; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous